Energia eòlica

含有生育酚结构的辅助脂质分子、包含其的脂质纳米颗粒及其用途

Resumen de: CN120647684A

本发明涉及含有生育酚结构的辅助脂质分子、包含其的脂质纳米颗粒及其用途。具体地，提供一种式(1)所示的含有生育酚及其衍生物结构的辅助脂质分子、包含其的脂质纳米颗粒、其制备方法和用途。与本领域常规使用的辅助脂质分子相比，本发明的式(1)所示的辅助脂质分子所制备得到的脂质纳米颗粒可显著提高核酸的递送效率及表达。#imgabs0#

宠物用吡虫啉莫昔克丁慢释药物制剂

Resumen de: CN120643568A

本发明属于宠物杀虫剂技术领域，具体涉及宠物用吡虫啉莫昔克丁慢释药物制剂。宠物用吡虫啉莫昔克丁慢释药物制剂，包括以下组分：活性成分：吡虫啉与莫昔克丁，其中吡虫啉的质量分数为5%‑20%，莫昔克丁的质量分数为1%‑10%；缓释载体：包括重量比2‑3:1的改性脂质纳米粒和聚合物微球，其质量分数为10%‑40%；透皮促进剂；稳定剂；pH调节剂；掩味剂：选自辣木籽油或薄荷脑，其质量分数为0.1%‑1%；余量为溶剂乙醇。本发明制备的宠物用吡虫啉莫昔克丁慢释药物制剂缓释效果好，稳定性高。

一种靶向递送姜黄素的成骨样细胞膜包被纳米粒及其制备方法与应用

Resumen de: CN120643533A

本发明涉及生物技术领域，公开了一种靶向递送姜黄素的成骨样细胞膜包被纳米粒及其制备方法与应用。所述成骨样细胞膜包被纳米粒，包括：姜黄素、聚乳酸‑羟基乙酸共聚物和MC3T3‑E1细胞膜；其中，所述聚乳酸‑羟基乙酸共聚物包裹所述姜黄素形成纳米颗粒，所述MC3T3‑E1细胞膜包裹所述纳米颗粒形成所述成骨样细胞膜包被纳米粒。本发明的成骨样细胞膜包被纳米粒具有骨组织靶向性，在减少副作用的同时能够改善姜黄素稳定性与生物利用度，且还能同步抑制骨吸收与促进骨形成，为骨质疏松的有效治疗提供了一种新策略。

包含含硅材料的递送体系

Resumen de: US2022183989A1

A method for promoting the controlled binding and release of a bioactive or pharmaceutical agent from a composition comprising silicon nanoparticles, wherein the silicon nanoparticles comprise at least 50% by weight silicon, the method comprising treating the surface of the silicon nanoparticles with at least one lipid, and treating the surface of the silicon nanoparticles with at least one amino acid, wherein the ratio of lipid to silicon is from 1:1 to 15:1. Also related compositions and methods.

基于不同形貌PLGA纳米颗粒的关节炎治疗体系及制备方法

Resumen de: CN120643534A

本发明公开了一种基于不同形貌PLGA纳米颗粒的关节炎治疗体系及制备方法，所述关节炎治疗体系包括棒状的载药PLGA纳米颗粒和盘状的N‑乙酰基神经氨酸修饰的PLGA纳米颗粒；制备方法包括以下步骤：分别制备棒状的载药PLGA纳米颗粒和盘状的N‑乙酰基神经氨酸修饰的PLGA纳米颗粒；将两者进行混合，获得所述基于不同形貌PLGA纳米颗粒的关节炎治疗体系。本发明能够克服临床使用的类风湿型关节炎药物生物利用率低、对免疫系统毒副作用大的缺陷，提供一种能够阻断中性粒细胞炎症募集且不影响其活性的类风湿性关节炎治疗体系。

一种具有协同作用的治疗癌症转移药物组合物及其制备方法和应用

Resumen de: CN120643535A

本发明涉及医疗药物领域，具体涉及一种具有协同作用的治疗癌症转移药物组合物及其制备方法和应用，本发明包括，丝素蛋白包裹的Cu2‑xS‑PEI‑Lapachone纳米粒子，表示为Cu2‑xS‑PEI‑Lapachone‑SFNs。采用本发明的技术方案，用于通过Cu2‑xS、Lapachone、丝素蛋白进行协同作用促进抑制癌症能力。

用于治疗弱精症的药物

Resumen de: CN120617313A

本发明公开了一种用于治疗弱精症的药物，以脐带间充质干细胞UCMSC构建细胞外囊泡，并封装BITT或ATP；将UCMSC‑EVs与BITT或溶解于磷酸盐缓冲溶液PBS中的ATP混合，并在黑暗中于37℃孵育1小时，通过超速离心浓缩得到所述的用于治疗弱精症的药物。本发明采用了多功能脐带间充质干细胞外泌体，其中包裹了三磷酸腺苷，以协同恢复细胞能量并抑制铁死亡，通过结合成像精度与双重治疗模式，这种方法有望克服BTB的局限性，解决男性不育问题。

包含核酸、可电离脂质、固醇、脂质锚定聚合物和辅助脂质的脂质纳米颗粒、其用途

Resumen de: AU2023406303A1

Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.

合成单链DNA分子及其产生和使用方法

Resumen de: AU2023406947A1

The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.

联合维奈克拉协同增强自然杀伤细胞免疫治疗的纳米接合器及应用

Resumen de: CN120617204A

本发明公开了一种联合维奈克拉协同增强自然杀伤细胞免疫治疗的纳米接合器及在应用，属于生物医药与纳米技术交叉领域。本发明通过赋形剂分子与维奈克拉共沉淀制备纳米颗粒，改善药物疏水性，通过免疫激活‑靶点阻断的双功能抗体修饰，实现化疗药物与免疫细胞治疗的时空协同。本发明对于抗血液恶性肿瘤药物的研发、药效研究及白血病细胞耐药性研究等临床及科研领域具有极大的应用潜力。

一种纳米级超细粉的防团聚制备装置及方法

Resumen de: CN120618339A

本发明属于纳米材料制备技术领域，具体涉及一种纳米级超细粉体的防团聚制备装置及方法。纳米级羟基磷灰石简称nHA，是一种纳米级的超细粉，在常温常压的空气暴露环境，容易发生团聚现象，团聚成更大颗粒度的物质。本发明使用改性酪蛋白作为填充物，使nHA颗粒复合分散在填充物中，有效防止纳米团聚效应的发生。成本相对较低，适合大规模工业化应用。

一种包裹卵黄抗体的植物外泌体样囊泡及其制备方法和应用

Resumen de: CN120617201A

本发明公开了包裹卵黄抗体的植物外泌体样囊泡的制备方法，包括如下步骤：将稳定修饰后的植物源外泌体样囊泡复溶，得到复溶后的植物源外泌体样囊泡；将复溶后的植物源外泌体样囊泡进行冷冻；重复S1和S2操作多次，将植物源外泌体样囊泡再次复溶；取卵黄抗体，用PBS缓冲液超声溶解后备用，得到卵黄抗体溶液；将卵黄抗体溶液与再次复溶的植物源外泌体样囊泡混合后，进行孵育，得到包裹卵黄抗体的植物外泌体样囊泡；将包裹卵黄抗体的植物外泌体样囊泡复溶后，进行真空冻干，保存备用，制得包裹卵黄抗体的植物外泌体样囊泡。本发明用以解决幽门螺杆菌感染较多的技术问题。

SITE-SPECIFIC CONJUGATION OF TARGETING MOIETIES TO LIPID NANOPARTICLES

Resumen de: WO2025189161A1

The disclosure provides Fab fragments that are site-selectively conjugated to the surface of a lipid nanoparticle (LNP) through the natural interchain disulfide bond between the heavy chain and the light chain (i.e., the CL-CH1 disulfide bond) to make targeted LNPs (also referred to herein as conjugates). The targeted LNPs (conjugates) produced by the methods disclosed herein can transduce specific targeted cells. Hence, the targeted LNPs are capable of delivering therapeutic payloads to cells to treat disease in a subject.

POLYMER MODIFIED NANOPARTICLES FOR CYTOKINE OR OTHER PAYLOAD DELIVERY

Resumen de: WO2025188498A1

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

METHOD FOR MANUFACTURING POROUS SILICON NANOPARTICLES BY MEANS OF ULTRASONIC TREATMENT

Resumen de: WO2025188061A1

The present invention relates to a method for manufacturing porous silicon nanoparticles by means of ultrasonic treatment. A novel ultrasonic treatment apparatus using a duty cycle scheme was fabricated, and physical properties such as optimized conditions of the apparatus, yield, size, size distribution, surface state, shape, pore size, and drug delivery capacity of the porous silicon nanoparticles manufactured by the duty cycle scheme were analyzed. The duty cycle scheme was confirmed to exhibit a significantly higher yield of porous silicon nanoparticles compared to conventional schemes, and the porous silicon nanoparticles manufactured by the duty cycle scheme exhibited similar physical properties to those of porous silicon nanoparticles manufactured by the conventional schemes. Therefore, it was confirmed that the method for manufacturing porous silicon nanoparticles by means of ultrasonic treatment using the duty cycle scheme of the present invention is suitable for mass production.

COMPOSITIONS AND METHODS OF USING GENE CODING FOR TREATING OCULAR DISEASE

Resumen de: WO2025188836A1

The present disclosure describes methods of using lipid nanoparticle (LNP) compositions for treating ocular- related disorders or diseases. In particular, methods are provided for using LNP compositions in gene therapy for targeting an ATP binding cassette subfamily A member 4 (ABCA4) or a functional fragment thereof, in a subject, thereby treating or mitigating Inherited Macular Degenerations including a Stargardt disease or other diseases that involve retinal degeneration.

LIPID NANOPARTICLE

Resumen de: WO2025187760A1

The purpose of the present invention is to provide a lipid nanoparticle that makes it possible to efficiently introduce a drug into a cell, and a constituent lipid of this lipid nanoparticle. Provided are: a compound represented by general formula (I), (II), or (III); a salt or stereoisomer thereof; and a lipid nanoparticle containing the same as a constituent lipid.

IRON-OXIDE NANOPARTICLE-LOADED MESENCHYMAL STEM CELLS AND USES THEREOF

Resumen de: WO2025184767A1

A composition that includes a stem cell and a coated iron oxide nanoparticle. The coated iron oxide nanoparticle, being present in the cytoplasm of the stem cell, contains a superparamagnetic iron oxide core that is coated with one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker covalently linking the polyethylene glycol group and the silane group. Also provided is a method for treating an inflammatory disorder in which stem cells are cultured in the presence of coated iron oxide nanoparticles and the cultured stem cells are administered to a subject suffering from an inflammatory disorder. Further disclosed is a method for tracking stem cells in vivo by labeling stem cells with coated iron oxide nanoparticles, administering the labeled stem cell to an individual, and obtaining one or more T2 weighted magnetic resonance images of the individual to track the stem cells.

LIPID NANOPARTICLE COMPOSITIONS INCORPORATING AN IMMUNOSUPPRESSANT FOR THE DELIVERY OF SELF-AMPLIFYING RNA

Resumen de: WO2025184750A1

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and/or variants thereof for use in CRISPR-based gene editing.

NANOPARTICLES AND USES THEREOF

Resumen de: WO2025184694A1

The present disclosure relates generally to nanoparticles and compositions comprising the same, and their use for transfecting transfection-recalcitrant cells, wherein the nanoparticle is tethered to an antigen-binding moiety having binding specificity for an antigen expressed on the surface of the cell, such as cluster of differentiation 2 (CD2) or cluster of differentiation 7 (CD7), wherein the nanoparticle comprises at least an ionisable lipid and a sterol.

POLYSACCHARIDE COMPOSITION, NANO POLYSACCHARIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025185570A1

A polysaccharide composition, a nano polysaccharide, a preparation method therefor, and use thereof. The polysaccharide composition comprises a polysaccharide and a lipid material. The weight ratio of the polysaccharide to the lipid material is 2-50:1.

一种仿生纳米囊泡及其制备方法和应用

Resumen de: CN120617207A

本发明公开了一种仿生纳米囊泡制备方法，包括以下步骤：将表没食子茶素没食子酸酯和硒代蛋氨酸溶于去离子水中，加入甲醛溶液在黑暗环境中搅拌，离心纯化，得球形纳米颗粒；从干细胞中提取外泌体；将球形纳米颗粒与外泌体加入去离子水中搅拌得仿生纳米囊泡。本发明制备的仿生纳米囊泡可对巨噬细胞和T细胞的进行调控，具有抗炎和调控免疫网络作用，应用于对急性肾损伤的保护作用。

一种能够控制纳米颗粒尺寸与球形度的制备方法

Resumen de: CN120617209A

本发明涉及一种能够控制纳米颗粒尺寸与球形度的制备方法，包括如下步骤：1）首先将乙醇溶液添加到牛血清白蛋白中进行去溶剂化得到原料液，再将原料液与适量乙醇、适量戊二醛合并成待处理溶液；2）待处理溶液转移至倾斜放置的涡旋流体装置中以转速n旋转时间T得到处理液；3）将处理液离心、洗涤后得到所述纳米颗粒。通过对涡旋流体装置轴线与水平位置的夹角、处理时间、旋转速度等多参数协同调控，实现了对牛血清白蛋白纳米颗粒的尺寸、形貌，以及球形度的精准控制，可灵活制备不同尺寸、孔径及比表面积的纳米颗粒，满足肿瘤靶向、疫苗载体等多场景需求。

一种明胶-透明质酸可注射水凝胶携载药纳米颗粒复合材料及其制备方法和应用

Resumen de: CN120617149A

本发明公开了一种明胶‑透明质酸可注射水凝胶携载药纳米颗粒复合材料及其制备方法和应用，涉及生物医学技术领域，解决现有技术中现有软骨相关疾病治疗用药物递送难，不能同时有效控制关节腔内的慢性炎症反应并保护软骨细胞，限制了药物的应用效果的技术问题。本发明制备方法，包括S1、获得肌肽修饰的透明质酸衍生物Car‑HA；S2、制备负载非诺贝特的纳米颗粒FNPs；S3、将含FNPs的明胶溶液与Car‑HA溶液混合，向上述混合体系中加入转谷氨酰胺酶，进行酶促交联反应，形成稳定网络结构的水凝胶FNPs‑GelHA。本发明所提出的Car‑HA与FNPs协同水凝胶策略具有良好的结构可调性和药物适应性，适用于多种抗炎、抗氧化、软骨修复类药物的递送，可广泛应用于软骨相关疾病的局部精准治疗。

一种脂滴仿生纳米粒子药物递送系统及其制备方法和应用

Nº publicación: CN120617202A 12/09/2025

Solicitante:

上海市同济口腔医院（同济大学附属口腔医院）

Resumen de: CN120617202A

本发明提供一种脂滴仿生纳米粒子药物递送系统及其制备方法和应用。该脂滴仿生纳米粒子药物递送系统的尺寸在纳米级别，符合有效纳米医学应用的标准，增强组织渗透和细胞吸收；水溶性良好，可应用于临床牙周炎的药物注射治疗，现配现用；具有低细胞毒性和良好的生物相容性。